Related Experiment Video

Updated: Feb 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.5K

Intravenous immunoglobulin G as adjuvant treatment in drug-resistant childhood epilepsy

Z González-Castillo1, E Solórzano Gómez1, A Torres-Gómez2

  • 1Departamento de Neurología Pediátrica, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.

Neurologia
|December 3, 2017
PubMed

Insights

Intravenous immunoglobulin G (iIV IgG) shows promise in reducing seizure frequency and duration for pediatric patients with drug-resistant epilepsy. This adjuvant therapy offers a potential new treatment avenue for difficult-to-manage childhood epilepsy cases.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Epilepsy is a common childhood neurological disorder, with drug-resistant epilepsy affecting 10-23% of pediatric patients.
  • Identifying effective treatments for drug-resistant epilepsy in children is a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of adding intravenous immunoglobulin G (iIV IgG) as an adjuvant therapy.
  • To assess the impact of iIV IgG on seizure frequency and duration in pediatric patients with drug-resistant epilepsy.

Main Methods:

  • An analytic, observational, retrospective case-control study was conducted.
  • Paediatric patients with drug-resistant epilepsy treated with iIV IgG between 2003 and 2013 were analyzed.
  • Seizure frequency and duration were compared before and after the initiation of iIV IgG treatment.

Main Results:

  • Out of 167 patients with drug-resistant epilepsy, 44 received adjuvant iIV IgG therapy.
  • A significant reduction in seizure duration (66.66%) was observed at 2 months post-treatment.
  • Seizure frequency decreased by 64% at 4 months after initiating iIV IgG (P<.001).

Conclusions:

  • Intravenous immunoglobulin G (iIV IgG) demonstrates potential as an effective adjunctive therapy.
  • iIV IgG may significantly reduce seizure frequency and duration in pediatric drug-resistant epilepsy.
  • This finding suggests a new therapeutic option for managing refractory childhood epilepsy.
Abstract

Keywords:
Crisis epilépticaDrug-resistant epilepsyEpilepsia farmacorresistenteIV immunoglobulin GInmunoglobulina G ivSeizures

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
711
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
957
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
33